Incannex Healthcare (ASX: IHL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Incannex Healthcare Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Incannex Healthcare (ASX: IHL)
    Latest News

    An older farmer wearing a checkered shirt and a straw hat stands in a green field of cannabis plants growing up to waist level as he smiles while thinking about the outlook for ASX cannabis shares in FY23
    Cannabis Shares

    These were the best performing ASX cannabis shares in October

    These were the outperformers in the ASX cannabis shares basket in October.

    Read more »

    a woman holds a newly-sprouted cannabis plant in a ball of soil as she walks along a path in a farm where crops are growing either side.
    Share Gainers

    Incannex (ASX:IHL) share price leaps 6% on manufacturing update

    Sprouts of green appear for Incannex shares this morning after a market update.

    Read more »

    A man in a wheelchair stretches both arms into the air in success.
    Healthcare Shares

    How did ASX healthcare shares perform in the FY22 first quarter?

    ASX healthcare shares have pivoted from the major benchmarks in Q1 to book gains.

    Read more »

    A woman holds her hands to her face in shock and fear with a worried expression on her face as many ASX 200 shares hit 52-week lows today
    Healthcare Shares

    The Incannex (ASX:IHL) share price has lost 20% in 4 weeks. What's happening?

    Incannex shares recently reversed their upward momentum. Read on for more details.

    Read more »

    Falling cannabis asx share price represented by cannabis leaves on a declining line graph
    Share Market News

    What's going wrong for ASX cannabis shares lately?

    Why Aussie cannabis companies are worth watching right now...

    Read more »

    Share Gainers

    The Incannex (ASX:IHL) share price is up 40% in a month. Here's why

    Incannex has been on an extended run lately. Here are the details.

    Read more »

    women working with medicinal marijuana, indicating a share price movement in ASX cannabis shares
    Cannabis Shares

    Why the Incannex (ASX:IHL) share price is rocketing 170% in 2021

    Investors are seemingly optimistic on the healthcare company.

    Read more »

    rising medical asx share price represented by excited doctors dancing in ward
    Share Gainers

    Why the Incannex (ASX:IHL) share price leapt 9% today

    Incannex shares are on the move after the company updated investors on its next moves.

    Read more »

    range of hemp oil and skin products representing elixinol share price
    Cannabis Shares

    Incannex (ASX:IHL) share price flat after earnings report

    Shares in the medicinal cannabis company remain in the starter block today despite progress detailed in its quarterly results.

    Read more »

    Share Market News

    Incannex (ASX:IHL) share price up on patent application announcement

    Shares in the medicinal cannabis pharmaceutical company were released from a trading halt today.

    Read more »

    health worker wearing personal protective equipment and gesturing stop with her hands
    Share Market News

    Here's why Incannex (ASX:IHL) shares are in a trading halt

    The pharmaceutical up-and-comer has requested trading in its shares be placed on hold.

    Read more »

    A doctor looks unsure, indicating share price uncertainty for ASX medical companies
    Share Market News

    Incannex (ASX:IHL) share price backtracks on FDA update

    The Incannex Healthcare Ltd (ASX: IHL) share price is in reverse today despite announcing a positive update. We take a…

    Read more »

    Frequently Asked Questions

    Incannex listed on the ASX in May 2007.

    No, Incannex has not yet paid out any dividends.

    IHL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Incannex Healthcare

    Incannex Healthcare Ltd (ASX: IHL) is a developer of cannabinoid and psychedelic compound medicines. It is currently involved in clinical programs for the treatment of six conditions: Obstructive Sleep Apnea (OSA), Generalised Anxiety Disorder (GAD), traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions.

    The company has an Australian license to import, export, and distribute medicinal cannabis products and has a line of cannabinoid products.

    The Incannex share price hit an all-time high of $5.36 a couple of months after listing in May 2007 before plunging to its current levels.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    31 Oct 2023 Peter Widdows Buy 230,954 $15,296
    On-market trade. As per announcement on 07-11-2023
    31 Oct 2023 Peter Widdows Buy 280,000 $18,545
    On-market trade.
    02 Jun 2023 Joel Latham Buy 1,583,227 $1,583
    As advised by the company. Purchase of Loyalty Options
    02 Jun 2023 Troy Valentine Buy 2,443,413 $2,443
    As advised by the company. Purchase of Loyalty Options
    02 Jun 2023 Peter Widdows Buy 1,104,913 $1,104
    As advised by the company. Purchase of Loyalty Options

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Troy Robert Valentine Non-Executive ChairmanNon-Executive Director Dec 2017
    Troy Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartley s Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
    Mr Peter Widdows Non-Executive Director Mar 2018
    Mr Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartleys Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
    Mr Joel Bradley Latham Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Joel Latham is the CEO and Managing Director of Incannex Healthcare and is responsible for the Companys commercial operations, strategic decision- making, and oversight of all clinical development assets. Joel has over 15 years commercial management and executive experience, working for a range multi-national publicly traded companies.
    Dr George Anastassov Non-Executive Director Jun 2022
    Dr Anastassov is responsible for APIRx commercial operations, strategic decision-making, and oversight of all clinical development assets. He is one of the developers of the first-in-the world cannabinoid-containing chewing gum-based delivery system among a number of other systems and formulations. Previously, he was CEO and co-founder of AXIM Biotechnologies, which achieved an all-time-high market capitalization of approximately US$1.2B.
    Mr Lekhram Changoer Non-Executive Director Jun 2022
    --
    Mr Robert Bruce Clark Non-Executive Director Aug 2022
    Mr Clark is a senior-level strategic regulatory affairs expert with over 38 years of US and Global regulatory experience, including >20 years with Pfizer Inc. and >10 years with Novo Nordisk A/S. He is an internationally recognized expert on US Food and Drug Administration ('FDA') and the European Medicines Agency (EMA) liaison interactions, US pharmaceutical advertising practices and regulatory aspects related to healthcare professionals and sales force activities. Mr Clark is Vice President, US Regulatory Affairsfor Novo Nordisk where he provides strategic leadership to a team of over 50 regulatory staff and scientists in the development of new medicines. He advises the global executive team on matters related to drug development programs, FDA liaison strategies, managing FDA-related compliance issues, and monitoring emerging US regulatory trends and opportunities.
    Mr Madhukar (Madhu) Bhalla Company Secretary Jul 2021
    -
    Madhukar (Madhu) Bhalla Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 82,707,741 5.23%
    George Anastassov 66,972,077 4.23%
    Prasch Bv 63,954,841 4.04%
    Dr Sudhanshu Agarwal 34,080,364 2.15%
    Cannvalate Pty Ltd 32,000,000 2.02%
    Mr Raymond Laurence Carroll 30,250,000 1.91%
    J P Morgan Nominees Australia Pty Limited 23,906,440 1.51%
    Brownarrows Pty Ltd <Ejm A/C> 23,610,000 1.49%
    BNP Paribas Noms Pty Ltd Deutsche Bank Tca <Drp> 22,880,950 1.45%
    Citicorp Nominees Pty Limited 19,087,124 1.21%
    Mr Peter Widdows 15,973,694 1.01%
    Mr Kaide Wang 15,700,000 0.99%
    IMI LLC 14,642,234 0.93%
    Bagbo Pty Ltd 14,516,434 0.92%
    Mr Brian Peter Byass 14,247,191 0.90%
    Mr Joel Bradley Latham 13,829,129 0.87%
    Gemini Capitall Llc <The Ars A/C> 13,787,086 0.87%
    Slade Technologies Pty Ltd <Embrey Family S/F A/C> 13,350,000 0.84%
    Alignment Capital Pty Ltd 13,194,248 0.83%
    Ryba Llc 13,090,170 0.83%

    Profile

    since

    Note